Autologous Tumor-Infiltrating Lymphocytes Effective for Treatment of Metastatic Melanoma

Source: Targeted Oncology, June 2020

Lifileucel (LN-144) showed a favorable overall response rate in patients with pretreated metastatic melanoma, according to initial data from cohort 4 of the phase 2 C-144-01 trial. The developer of lifileucel, Iovance Biotherapeutics, Inc, plans to submit a Biologics License Application to the FDA, based on these findings.1

“We are very pleased to announce our pivotal cohort 4 early data from the C-144-01 clinical study in advanced melanoma today,” said Maria Fardis, PhD, president and CEO of Iovance Biotherapeutics, in a statement.

At a median follow-up of 5.3 months, the objective response rate (ORR) observed in the 68-patient cohort was 32.4%, which included partial responses (PRs) in 21 patients, 2 of which were pending confirmation at data cutoff, and one complete response (CR). The disease control rate (DCR) was 72.1%.

READ THE ORIGINAL FULL ARTICLE